Abstract PD5-06: Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials
Saranya Chumsri(Jacksonville College), E. Aubrey Thompson(Mayo Clinic in Florida), K. Tenner(University of Helsinki), Alvaro Moreno‐Aspitia(University of Helsinki), DJ Serie(University of Helsinki), Afshin Mashadi-Hossein(University of Helsinki), SL Lauttia(University of Helsinki), Henrik Lindman(Uppsala University), Amin H. Nassar(Brigham and Women's Hospital), Heikki Joensuu(Orion Corporation (Finland)), Patrick Danaher(Nanostring Technologies (United States)), G. Colon-Otero(University of Helsinki), Stephen L. Warren(University of Helsinki), EA Perez(University of Helsinki), SA McLaughlin(University of Helsinki)
Cited by 0
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k